Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

Table 3 Characteristics matching in Risperidone ISM versus Aripiprazole monohydrate once-monthly comparison, for the tolerability base case analysis

Study	PRISMA-3 OLE (Full population)		Kane 2012 [30] (AOM arm)
Intervention	Risperidone ISM		AOM
Characteristic	Pre-matching (N = 215)	Post-matching (ESS = 26)	(N = 269)
Age [Mean (SD)]	39.1 (10.9)	40.1 (11.0)	40.1 (11.0)
Baseline PANSS total score [Mean]	71.3	54.5	54.5
Baseline CGI-S total score [Mean]	3.5	2.9	2.9
Race: white [%]	84.7	56.5	56.5

AOM aripiprazole monohydrate once-monthly, CGI-S clinical global impressions—severity scale, ESS effective sample size, OLE open-label extension, PANSS positive and negative syndrome scale, SD standard deviation

ISSN: 1744-859X